Skip to main content
NCBI home page
Biochemical Journal logoLink to Biochemical Journal
. 1990 Oct 1;271(1):51–57. doi: 10.1042/bj2710051

The mechanism of activation of plasminogen at the fibrin surface by tissue-type plasminogen activator in a plasma milieu in vitro. Role of alpha 2-antiplasmin.

D Rouy 1, E Anglés-Cano 1
PMCID: PMC1149513  PMID: 1699517

Abstract

The mechanism of activation of human Glu-plasminogen by fibrin-bound tissue-type plasminogen activator (t-PA) in a plasma environment or in a reconstituted system was characterized. A heterogeneous system was used, allowing the setting of experimental conditions as close as possible to the physiological fibrin/plasma interphase, and permitting the separate analysis of the products present in each of the phases as a function of time. The generation of plasmin was monitored both by spectrophotometric analysis and by radioisotopic analysis with a plasmin-selective chromogenic substrate and radiolabelled Glu-plasminogen respectively. Plasmin(ogen)-derived products were identified by SDS/PAGE followed by autoradiography and/or immunoblotting. When the activation was performed in a plasma environment, the products identified on the fibrin surface were Glu-plasmin (90%) and Glu-plasminogen (10%), whereas in the soluble phase only complexes between Glu-plasmin and its fast-acting inhibitor were detected. Identical results were obtained with a reconstituted system comprising solid-phase fibrin, t-PA, Glu-plasminogen and and alpha 2-antiplasmin. In contrast, when alpha 2-antiplasmin was omitted from the solution, Lys-plasmin was progressively generated on to the fibrin surface (30%) and released to the soluble phase. In the presence of alpha 2-antiplasmin or in plasma, the amount of active plasmin generated on the fibrin surface was lower than in the absence of the inhibitor: in a representative experiment the initial velocity of plasmin generation was 2.8 x 10(-3), 2.0 x 10(-3) and 1.8 x 10(-3) (delta A405/min) for 200 nM-plasminogen, 200 nM-plasminogen plus 100 nM-alpha 2-antiplasmin and native plasma respectively. Our results indicate that in plasma or in a reconstituted purified system containing plasminogen and alpha 2-antiplasmin at a ratio similar to that found in plasma (1) the activation pathway of native Glu-plasminogen proceeds directly to the formation of Glu-plasmin, (2) Lys-plasminogen is not an intermediate of the reaction and therefore (3) Lys-plasmin is not the final active product. However, in the absence of the inhibitor, Lys-plasmin and probably Lys-plasminogen, which is more readily activated to plasmin than is Glu-plasminogen, are generated as well.

Full text

PDF
51

Images in this article

53Fig. 1.
on p.53
55Fig. 3.
on p.55

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Angles-Cano E. A spectrophotometric solid-phase fibrin-tissue plasminogen activator activity assay (SOFIA-tPA) for high-fibrin-affinity tissue plasminogen activators. Anal Biochem. 1986 Mar;153(2):201–210. doi: 10.1016/0003-2697(86)90082-5. [DOI] [PubMed] [Google Scholar]
  2. Anglés-Cano E., Boutière B., Arnoux D., Masson C., Contant G., Benchimol P., Sampol J. Release pattern of the vascular plasminogen activator and its inhibitor in human postvenous occlusion plasma as assessed by a spectrophotometric solid-phase fibrin-tPA activity assay. Thromb Haemost. 1987 Oct 28;58(3):843–849. [PubMed] [Google Scholar]
  3. Anglés-Cano E., Masson C., Grailhe P., Gaussem P., Le Bonniec B. Functional identification of t-PA in crude and purified systems. Thromb Res Suppl. 1988;8:123–130. doi: 10.1016/0049-3848(88)90161-2. [DOI] [PubMed] [Google Scholar]
  4. Aoki N., Sakata Y. Influence of alpha 2-plasmin inhibitor on adsorption of plasminogen to fibrin. Thromb Res. 1980 Jul 1;19(1-2):149–155. doi: 10.1016/0049-3848(80)90414-4. [DOI] [PubMed] [Google Scholar]
  5. Aoki N., Sakata Y., Matsuda M., Tateno K. Fibrinolytic states in a patient with congenital deficiency of alpha 2-plasmin inhibitor. Blood. 1980 Mar;55(3):483–488. [PubMed] [Google Scholar]
  6. Booth N. A., Bennett B. Plasmin-alpha 2-antiplasmin complexes in bleeding disorders characterized by primary or secondary fibrinolysis. Br J Haematol. 1984 Apr;56(4):545–556. doi: 10.1111/j.1365-2141.1984.tb02179.x. [DOI] [PubMed] [Google Scholar]
  7. Brommer E. J. The level of extrinsic plasminogen activator (t-PA) during clotting as a determinant of the rate of fibrinolysis; inefficiency of activators added afterwards. Thromb Res. 1984 Apr 15;34(2):109–115. doi: 10.1016/0049-3848(84)90067-7. [DOI] [PubMed] [Google Scholar]
  8. Deutsch D. G., Mertz E. T. Plasminogen: purification from human plasma by affinity chromatography. Science. 1970 Dec 4;170(3962):1095–1096. doi: 10.1126/science.170.3962.1095. [DOI] [PubMed] [Google Scholar]
  9. Engvall E., Ruoslahti E. Binding of soluble form of fibroblast surface protein, fibronectin, to collagen. Int J Cancer. 1977 Jul 15;20(1):1–5. doi: 10.1002/ijc.2910200102. [DOI] [PubMed] [Google Scholar]
  10. Fraker P. J., Speck J. C., Jr Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun. 1978 Feb 28;80(4):849–857. doi: 10.1016/0006-291x(78)91322-0. [DOI] [PubMed] [Google Scholar]
  11. Harpel P. C., Chang T. S., Verderber E. Tissue plasminogen activator and urokinase mediate the binding of Glu-plasminogen to plasma fibrin I. Evidence for new binding sites in plasmin-degraded fibrin I. J Biol Chem. 1985 Apr 10;260(7):4432–4440. [PubMed] [Google Scholar]
  12. Holvoet P., Lijnen H. R., Collen D. A monoclonal antibody specific for Lys-plasminogen. Application to the study of the activation pathways of plasminogen in vivo. J Biol Chem. 1985 Oct 5;260(22):12106–12111. [PubMed] [Google Scholar]
  13. Hoylaerts M., Rijken D. C., Lijnen H. R., Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem. 1982 Mar 25;257(6):2912–2919. [PubMed] [Google Scholar]
  14. Ichinose A., Mimuro J., Koide T., Aoki N. Histidine-rich glycoprotein and alpha 2-plasmin inhibitor in inhibition of plasminogen binding to fibrin. Thromb Res. 1984 Feb 15;33(4):401–407. doi: 10.1016/0049-3848(84)90079-3. [DOI] [PubMed] [Google Scholar]
  15. KAZAL L. A., AMSEL S., MILLER O. P., TOCANTINS L. M. THE PREPARATION AND SOME PROPERTIES OF FIBRINOGEN PRECIPITATED FROM HUMAN PLASMA BY GLYCINE. Proc Soc Exp Biol Med. 1963 Aug-Sep;113:989–994. doi: 10.3181/00379727-113-28553. [DOI] [PubMed] [Google Scholar]
  16. Koppert P. W., Huijsmans C. M., Nieuwenhuizen W. A monoclonal antibody, specific for human fibrinogen, fibrinopeptide A-containing fragments and not reacting with free fibrinopeptide A. Blood. 1985 Sep;66(3):503–507. [PubMed] [Google Scholar]
  17. Koppert P. W., Koopman J., Haverkate F., Nieuwenhuizen W. Production and characterization of a monoclonal antibody reactive with a specific neoantigenic determinant (comprising B beta 54-118) in degradation products of fibrin and of fibrinogen. Blood. 1986 Aug;68(2):437–441. [PubMed] [Google Scholar]
  18. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  19. Lijnen H. R., Hoylaerts M., Collen D. Isolation and characterization of a human plasma protein with affinity for the lysine binding sites in plasminogen. Role in the regulation of fibrinolysis and identification as histidine-rich glycoprotein. J Biol Chem. 1980 Nov 10;255(21):10214–10222. [PubMed] [Google Scholar]
  20. Lijnen H. R., Van Hoef B., Collen D. On the role of the carbohydrate side chains of human plasminogen in its interaction with alpha 2-antiplasmin and fibrin. Eur J Biochem. 1981 Nov;120(1):149–154. doi: 10.1111/j.1432-1033.1981.tb05682.x. [DOI] [PubMed] [Google Scholar]
  21. Masson C., Angles-Cano E. Kinetic analysis of the interaction between plasminogen activator inhibitor-1 and tissue-type plasminogen activator. Biochem J. 1988 Nov 15;256(1):237–244. doi: 10.1042/bj2560237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Müllertz S., Thorsen S., Sottrup-Jensen L. Identification of molecular forms of plasminogen and plasmin-inhibitor complexes in urokinase-activated human plasma. Biochem J. 1984 Oct 1;223(1):169–177. doi: 10.1042/bj2230169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Norrman B., Wallén P., Rånby M. Fibrinolysis mediated by tissue plasminogen activator. Disclosure of a kinetic transition. Eur J Biochem. 1985 May 15;149(1):193–200. doi: 10.1111/j.1432-1033.1985.tb08911.x. [DOI] [PubMed] [Google Scholar]
  24. Rákóczi I., Wiman B., Collen D. On the biological significance of the specific interaction between fibrin, plasminogen and antiplasmin. Biochim Biophys Acta. 1978 May 3;540(2):295–300. doi: 10.1016/0304-4165(78)90142-3. [DOI] [PubMed] [Google Scholar]
  25. Rånby M. Studies on the kinetics of plasminogen activation by tissue plasminogen activator. Biochim Biophys Acta. 1982 Jun 24;704(3):461–469. doi: 10.1016/0167-4838(82)90068-1. [DOI] [PubMed] [Google Scholar]
  26. Sakata Y., Aoki N. Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis. J Clin Invest. 1982 Mar;69(3):536–542. doi: 10.1172/JCI110479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Steiner J. P., Migliorini M., Strickland D. K. Characterization of the reaction of plasmin with alpha 2-macroglobulin: effect of antifibrinolytic agents. Biochemistry. 1987 Dec 15;26(25):8487–8495. doi: 10.1021/bi00399a068. [DOI] [PubMed] [Google Scholar]
  28. Suenson E., Lützen O., Thorsen S. Initial plasmin-degradation of fibrin as the basis of a positive feed-back mechanism in fibrinolysis. Eur J Biochem. 1984 May 2;140(3):513–522. doi: 10.1111/j.1432-1033.1984.tb08132.x. [DOI] [PubMed] [Google Scholar]
  29. Suenson E., Thorsen S. The course and prerequisites of Lys-plasminogen formation during fibrinolysis. Biochemistry. 1988 Apr 5;27(7):2435–2443. doi: 10.1021/bi00407a029. [DOI] [PubMed] [Google Scholar]
  30. Takada A., Takada Y. Activation pathway of glu-plasminogen to Lys-plasmin by urokinase. Thromb Res. 1982 Sep 15;27(6):671–677. doi: 10.1016/0049-3848(82)90005-6. [DOI] [PubMed] [Google Scholar]
  31. Takada A., Yoshida M., Takada Y. Autoradiographic and immunoblotting analyses of the activation pathways of plasminogen by urokinase and tissue plasminogen activator in the plasma or clotted plasma. Thromb Res. 1988 Jan 15;49(2):193–204. doi: 10.1016/0049-3848(88)90213-7. [DOI] [PubMed] [Google Scholar]
  32. Thorsen S., Müllertz S., Suenson E., Kok P. Sequence of formation of molecular forms of plasminogen and plasmin-inhibitor complexes in plasma activated by urokinase or tissue-type plasminogen activator. Biochem J. 1984 Oct 1;223(1):179–187. doi: 10.1042/bj2230179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350–4354. doi: 10.1073/pnas.76.9.4350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Tran-Thang C., Kruithof E. K., Atkinson J., Bachmann F. High-affinity binding sites for human Glu-plasminogen unveiled by limited plasmic degradation of human fibrin. Eur J Biochem. 1986 Nov 3;160(3):599–604. doi: 10.1111/j.1432-1033.1986.tb10080.x. [DOI] [PubMed] [Google Scholar]
  35. Váradi A., Patthy L. Location of plasminogen-binding sites in human fibrin(ogen). Biochemistry. 1983 May 10;22(10):2440–2446. doi: 10.1021/bi00279a021. [DOI] [PubMed] [Google Scholar]
  36. Wallén P., Wiman B. Characterization of human plasminogen. II. Separation and partial characterization of different molecular forms of human plasminogen. Biochim Biophys Acta. 1972 Jan 26;257(1):122–134. doi: 10.1016/0005-2795(72)90261-9. [DOI] [PubMed] [Google Scholar]
  37. Werren J. H., Charnov E. L. Facultative sex ratios and population dynamics. Nature. 1978 Mar 23;272(5651):349–350. doi: 10.1038/272349a0. [DOI] [PubMed] [Google Scholar]
  38. Wiman B., Collen D. On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem. 1978 Mar 15;84(2):573–578. doi: 10.1111/j.1432-1033.1978.tb12200.x. [DOI] [PubMed] [Google Scholar]
  39. Wiman B., Collen D. On the mechanism of the reaction between human alpha 2-antiplasmin and plasmin. J Biol Chem. 1979 Sep 25;254(18):9291–9297. [PubMed] [Google Scholar]
  40. Wiman B., Wallén P. Activation of human plasminogen by an insoluble derivative of urokinase. Structural changes of plasminogen in the course of activation to plasmin and demonstration of a possible intermediate compound. Eur J Biochem. 1973 Jul 2;36(1):25–31. doi: 10.1111/j.1432-1033.1973.tb02880.x. [DOI] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES